Sang-Kwan Moon

Sang-Kwan Moon

Auto-generated profile, based on publicly available information

Sang-Kwan Moon

Kyung Hee University College of Korean Medicine, Kyung Hee University Medical Center, Seoul, Republic of Korea

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Integrative Medicine Research
Verified
Journal Article
Open access
SKSeungwon Kwon
Seungwon Kwon
WLWonhaeng Lee
Wonhaeng Lee
CJChul Jin
Chul Jin
IJInsoo Jang
Insoo Jang
WJWoo-Sang Jung
Woo-Sang Jung
KCKi-Ho Cho
Ki-Ho Cho
While the world struggles under the coronavirus disease 2019 (COVID-19) pandemic, a variety of antiviral agents and symptomatic treatments are being administered to patients and urgent clinical trials are underway. Under these circumstances, it is important to explore various possibilities for the treatment of COVID-19 including herbal medicines. Among various herbal medicines, Soshihotang (SSHT, Xiao Chai Hu Tang in Chinese) has been prescribed to treat various viral diseases and is used in combination with other herbal medicines depending on the patient’s symptoms. For conducting the present review, we searched electronic databases focusing on the antiviral effect of SSHT in experimental and clinical study until April 2020. The search keywords included SSHT, constituents of SSHT, and antiviral effect. We also searched for materials related to topic directly from websites and published books. Based on these search results, we summarized the results of the included materials in the form of a narrative review. In a number of recent clinical studies, treatment with SSHT improved the infection status of the respiratory and hepatobiliary systems, and experimental studies demonstrated the antiviral effect of SSHT and its components. Furthermore, SSHT are being used in China—where COVID-19 outbreak first took place—and offer a new option to treat COVID-19. Based on the present evidences, it is believed that SSHT is likely to be a new therapeutic option for COVID-19. Conducting further studies might provide improved understanding regarding the use of SSHT in treating COVID-19.

14 December 2021 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
CJChul Jin
Chul Jin
SKSeungwon Kwon
Seungwon Kwon
SCSeung-Yeon Cho
Seung-Yeon Cho
SPSeong-Uk Park
Seong-Uk Park
WJWoo-Sang Jung
Woo-Sang Jung
KCKi-Ho Cho
Ki-Ho Cho
Poststroke fatigue (PSF) is reported to occur in 3072 of all patients with stroke. PSF not only is a symptom of stroke but has also been reported to adversely affect the prognosis of patients with stroke. However, no treatment has had a significant effect on PSF. In East Asian countries, several herbal medicines have been used to treat stroke, with Buyang Huanwu Tang (BHT) being the most common. This review aimed to evaluate the efficacy and safety of BHT for PSF. A literature search was conducted on MEDLINE, CENTRAL, Scopus, CiNii, CNKI, OASIS, NDSL, and KTKP databases for randomized controlled trials that evaluated the effects and safety of BHT on PSF. Six studies (n=427) were included. The overall methodological quality of these studies was relatively low. In the adjunctive BHT group, the meta-analysis indicated statistically significant improvements in the Fatigue Severity Scale score (mean difference 1.49, 95 CI [2.25, 0.73]) and total clinical efficacy rate (risk ratio 0.11, 95 CI [0.03, 0.41]) compared to those in the nonherbal group. Adverse events were only reported in one study, and no serious adverse events occurred. BHT administration might be effective in the treatment of PSF. We were unable to draw definitive conclusions owing to the limitations of the included studies. The trial is registered with CRD42019130178 in PROSPERO.

6 December 2021 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
WSWon Joo Suh
Won Joo Suh
YSYuna Seo
Yuna Seo
CJChul Jin
Chul Jin
SCSeung-Yeon Cho
Seung-Yeon Cho
SPSeong-Uk Park
Seong-Uk Park
KCKi-Ho Cho
Ki-Ho Cho
This study aimed to analyze and summarize the existing evidence regarding herbal medicine treatments for amyotrophic lateral sclerosis (ALS). Studies on herbal medicine treatment in patients with ALS were searched within English, Chinese, Japanese, and Korean databases up to July 31, 2021. In the selected studies, we collected the following information: the first author, year of publication, country, language, study methodology, sample size, demographic characteristics of the study participants, disease duration, diagnostic criteria, treatment method, treatment periods, evaluation tools, results, and side effects. The organized data were classified and analyzed narratively. This study included 59 studies. The first clinical study on the effect of herbal medicine was published in 1995; moreover, most studies were conducted in China. Among the 59 selected studies, 47.5% were observational studies, including case reports and case series. Moreover, there was one meta-analysis. The El Escorial criteria were the most commonly used diagnostic criterion for ALS; moreover, the ALS functional rating scale was the most common evaluation tool. Buzhongyiqitang, Sijunzitangjiawei, and Jianpiyifeitang were the most commonly used herbal medicines, with anti-inflammatory, protein aggregation, and anti-oxidant effects. There remain evidence of gaps in the effectiveness of herbal medicine for ALS. To allow effective treatment of patients with ALS using herbal medicine, large-scale and rigorously designed high-quality clinical studies should be performed.

30 January 2023 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
HKHa-Ri Kim
Ha-Ri Kim
HSHee-Yeon Shin
Hee-Yeon Shin
TYTae-Bin Yim
Tae-Bin Yim
GJGeon-Ho Jahng
Geon-Ho Jahng
CJChul Jin
Chul Jin
JPJung-Mi Park
Jung-Mi Park
Background. Kami Guibi‐tang (KGT), a traditional Korean herbal medicine is mainly used to treat insomnia and nervousness. Acetylcholinesterase inhibitors (AChEIs) are the main treatments for mild Alzheimer’s disease (AD), a degenerative brain disease. However, currently no drug can fundamentally treat AD or reverse the advanced cognitive decline. This clinical study explored the efficacy and safety of adding KGT to AChEI for cognitive function in mild AD. Methods. This was a pilot study for a larger randomized, double‐blind, placebo‐controlled trial. Participants between 55–90 years diagnosed with mild AD were recruited from Kyung Hee University Hospital at Gangdong, Seoul, Korea. They were randomized to receive either KGT or placebo for 24 weeks, in addition to their regular AChEI. The primary outcome was treatment efficacy, as assessed by the relative amount of change over the study period in total scores on the Dementia version of the Seoul Neuropsychological Screening Battery (SNSB‐D). Changes in SNSB subscores were assessed as secondary outcomes. Safety parameters, including adverse events and abnormalities in blood tests, electrocardiograms, and brain magnetic resonance imaging were also monitored. Results. Between March 2018 and November 2020, seven participants each in the KGT group and the placebo group completed the 24‐week trial. There were no significant changes in SNSB‐D total or subindex scores for either group (p = 0.69 and 0.63, respectively), and no significant differences were observed between them (p = 0.71). No adverse events related to KGT were reported. We also compared and analyzed the results of a previous pilot study conducted on amnestic mild cognitive impairment (aMCI) using protocol of this study. The aMCI group showed a significant improvement in the total SNSB‐D score, especially in the memory domain, compared to the mild AD group (p = 0.04 and 0.02, respectively). The Korean Mini‐Mental State Exam and Korean Instrumental Activities of Daily Living scores also significantly improved in the aMCI group (p = 0.01 and 0.02, respectively). Conclusions. Compared to placebo, adding KGT to AChEI did not significantly improve cognitive function in SNSB in patients with mild AD. We suggest that KGT would have a positive effect on patients with early stages of cognitive impairment such as aMCI. The findings could assist design larger, longer‐term clinical trials of KGT use in elderly patients with mild AD. This study was registered in the Korean Clinical Trial Registry on December 26, 2017, with the CRIS approval number KCT0002904.

9 September 2021 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
HLHyun Ku Lee
Hyun Ku Lee
SMSang-Kwan Moon
Sang-Kwan Moon
CJChul Jin
Chul Jin
SCSeung-Yeon Cho
Seung-Yeon Cho
SPSeong-Uk Park
Seong-Uk Park
SKSeungwon Kwon
Seungwon Kwon
The Governing Vessel 14 (GV14) (Dazhui) is one of the acupuncture points referred to as “seven acupoints for stroke.” Nevertheless, there is a scarcity of research on the effects of acupuncture treatment at GV14. This study investigated the effects of acupuncture at GV14 on cerebral blood flow (CBF), especially that in the basilar artery (BA) and the middle cerebral arteries (MCA). Sixteen healthy men aged 20 to 29 years were enrolled in this study. CBF velocity and cerebrovascular reactivity (CVR) were measured using transcranial Doppler sonography (TCD). The following were assessed: closed circuit rebreathing- (CCR-) induced carbon dioxide (CO2) reactivity, modified blood flow velocity at 40 mmHg (CV40) on BA and MCAs, blood pressure (BP), and heart rate (HR). Observed results were obtained after comparison with the baseline evaluation. Statistically significant elevations in CO2 reactivity were recorded in the BA (3.28 to 4.70, ) and MCAs (right: 3.81 to 5.25, ; left: 3.84 to 5.12, ) after acupuncture at GV14. The CV40 increased statistically significantly only in the BA (45.49 to 50.41, ). No change was observed in BP (106.83 to 107.08 (mmHg), ) and HR (77 to 75 (bpm), ). Acupuncture at GV14 improved CBF velocity. These results could be explained by the regulation of endothelium-dependent vessel dilation effected by acupuncture. This trial is registered with Korean Clinical Trial Registry (http://cris.nih.go.kr; registration number: KCT0004787).

1 May 2021 in Complementary Therapies in Clinical Practice
Verified
Journal Article
Closed access
SKSeungwon Kwon
Seungwon Kwon
CJChul Jin
Chul Jin
MCMinho Chung
Minho Chung
JLJiEun Lee
JiEun Lee
SCSeung-Yeon Cho
Seung-Yeon Cho
KCKi-Ho Cho
Ki-Ho Cho